Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
Entasis Therapeutics Holdings announced that Dr. Manos Perros, CEO, will present at the virtual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entasis Therapeutics Holdings announced that Dr. Manos Perros, CEO, will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be accessible on demand starting January 11 at 6:00 AM ET. Entasis focuses on developing antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, with candidates including sulbactam-durlobactam and zoliflodacin, among others. For more details, visit www.entasistx.com.
Details
News Market Reaction – ETTX
The recorded move for ETTX in the trading session of this news was +5.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.
The Company’s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually.
About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com
Investor Relations Contact
James Salierno
The Ruth Group
(646) 536-7028
jsalierno@theruthgroup.com
Media Contact
Annika Parrish
The Ruth Group
(720) 412-9042
aparrish@theruthgroup.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.